Organigram snags Aurora for $401 million, and Curaleaf's hostile bid is left on the shelf

Organigram Global agreed on November 3 to acquire Aurora Cannabis for roughly $401 million, paying $5.57 a share. By Ganjapreneur's account, that is a 93 percent premium to Aurora's price before the saga began in August and about 21 percent above the implied value of Curaleaf's unsolicited bid as of November 2.

The deal effectively ends Curaleaf's hostile takeover attempt, which our newsroom has tracked since August. Curaleaf publicly responded on November 4 to what it called an alternative proposal; we could not retrieve that statement, so we are not characterizing it.

Aurora shareholders are expected to hold about 35 percent of the combined company economically and 42 percent of the votes. Both CEOs framed the deal around Aurora's international medical platform joining Organigram's Canadian operations.

For the sector, this is consolidation among Canadian producers rather than a U.S. plant-touching deal, but it matters to U.S. operators selling into export channels and watching how much a strategic buyer will pay for medical-focused scale. The hostile route did not win, and a negotiated route set the price.